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Abstract
Background: Salt-wasting represents a relatively common cause of emergency admission in infants and may result
in life-threatening complications. Neonatal kidneys show low glomerular filtration rate and immaturity of the distal
nephron leading to reduced ability to concentrate urine.
Methods: A retrospective chart review was conducted for infants hospitalized in a single Institution from 1st
January 2006 to 31st December 2015. The selection criterion was represented by the referral to the Endocrinology
Unit for hyponatremia (serum sodium <130 mEq/L) of suspected endocrine origin at admission.
Results: Fifty-one infants were identified. In nine infants (17.6 %) hyponatremia was related to unrecognized
chronic gastrointestinal or renal salt losses or reduced sodium intake. In 10 infants (19.6 %) hyponatremia was
related to central nervous system diseases. In 19 patients (37.3 %) the final diagnosis was congenital adrenal
hyperplasia (CAH). CAH was related to 21-hydroxylase deficiency in 18 patients, and to 3β-Hydroxysteroid
dehydrogenase (3βHSD) deficiency in one patient. Thirteen patients (25.5 %) were affected by different non-CAH
salt-wasting forms of adrenal origin. Four familial cases of X-linked adrenal hypoplasia congenita due to NROB1 gene
mutation were identified. Two unrelated girls showed aldosterone synthase deficiency due to mutation of
the CYP11B2 gene. Two unrelated infants were affected by familial glucocorticoid deficiency due to MC2R gene
mutations. One girl showed pseudohypoaldosteronism related to mutations of the SCNN1G gene encoding for
the epithelial sodium channel. Transient pseudohypoaldosteronism was identified in two patients with renal
malformations. In two infants the genetic aetiology was not identified.
Conclusions: Emergency management of infants presenting with salt wasting requires correction of water losses
and treatment of electrolyte imbalances. Nevertheless, the differential diagnosis may be difficult in emergency
settings, and sometimes hospitalized infants presenting with salt-wasting are immediately started on steroid
therapy to avoid life-threatening complications, before the correct diagnosis is reached. Physicians involved in
the management of infants with salt-wasting of suspected hormonal origin should remember that, whenever
practicable, a blood sample for the essential hormonal investigations should be collected before starting steroid
therapy, to guide the subsequent diagnostic procedures and in particular to address the analysis of candidate
genes.
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Background
Salt-wasting in newborns and infants represents a rela-
tively common cause of emergency admission to hospital
and may result in life-threatening complications. The
kidneys are responsible of electrolyte homoeostasis, but
neonatal kidneys show low glomerular filtration rate and
immaturity of the distal nephron leading to reduced ability
to concentrate urine. High extra-renal fluid losses often
contribute to the increased occurrence of electrolyte dis-
orders. Sodium is the main determinant of serum osmo-
lality, and changes in sodium concentration can result in
fluid shifts between intracellular and extracellular com-
partments. Water influx into the intracellular space swells
cells, which can cause cerebral oedema and neurologic
sequelae. Newborn and infants with hyponatremia (serum
sodium concentration <130 mEq/L) may present with
symptoms such as vomiting, irritability, hypotonia and
seizures. In the outpatient setting, hyponatremia in infants
is very uncommon, but can be caused by excess ingestion
of free water and hypotonic fluids, such as overdiluted
infant formula or plant milk, or by elevated salt loss with
diarrhoea. Most cases of hyponatremia occur in hospital-
ized infants due to administration of hypotonic fluids, but
also occur due to central nervous system pathology, lung
disease, or postoperative complications. Severe hyponatre-
mia with or without hyperkalemia, hypochloremia, meta-
bolic acidosis and fasting hypoglycemia is life-threatening
in newborns and infants and represents the most typical
presentation mode of congenital primary adrenal insuffi-
ciency (PAI). The most common form of PAI is the con-
genital adrenal hyperplasia (CAH) due to 21-hydroxylase
deficiency, accounting for more than 75 % of cases [1]. X-
linked adrenal hypoplasia congenital (AHC) and familial
glucocorticoid deficiency (FGD) represent individually
rare monogenic forms of PAI presenting with salt wasting
during infancy [1, 2]. Aldosterone synthase deficiency
(primary hypoaldosteronism) and aldosterone resistance
(pseudohypoaldosteronism: PHA) can mimic clinical
presentation of PAI, but glucocorticoid function is always
normal in these disorders. However, in many neonatal
cases not all the biochemical characteristic are evident at
clinical presentation. Hyponatremia is found in 90 % of
patients with PAI, while hyperkalemia is seen in only 50 %
of patients [1]. Severe salt-wasting with hyponatremia is
usually caused by selective mineralocorticoid deficiency,
PHA and complete PAI (both glucocorticoid and min-
eralocorticoid deficiency), but also infants with isolated
severe glucocorticoid deficiency (as patients with FGD)
and preserved aldosterone secretion may show transient
hyponatremia at presentation [1, 2].
Pseudohypoaldosteronism (PHA)
PHA is characterised by the renal tubular unresponsive-
ness to aldosterone and presents with hyponatremia,
hyperkalaemia and metabolic acidosis with elevated
plasma aldosterone and renin concentrations, but nor-
mal levels of ACTH and cortisol [3]. The differential
diagnosis between congenital PAI and PHA may be chal-
lenging in an emergency setting and sometimes new-
borns and infants presenting with severe hyponatremia,
hyperkalaemia, dehydration and metabolic acidosis are
immediately started on mineralocorticoid and gluco-
corticoid therapy to avoid life-threatening complications,
before the correct diagnosis is reached [4]. There are
two types of primary PHA: PHA1 is characterized by
failure to thrive, anorexia, nausea, and vomiting with
hypotension, hyperkalemia, hyponatremia and acidosis,
accompanied by high aldosterone levels; in contrast,
PHA2 or type four renal tubular acidosis is due to the
failure of the kidney to appropriately secrete potassium.
Individuals with PHA2 show early-onset hypertension
readily responsive to sodium restriction and thiazide di-
uretics, hyperkalemia, hyperchloremic acidosis, normal
or low plasma renin activity, and subnormal plasma al-
dosterone level relative to the potassium level [5]. PHA1
is further categorized into two forms: autosomal reces-
sive PHA1 due to a defect in the genes SCNN1A,
SCNN1B and SCNN1G encoding for the subunits α, β
and γ of the epithelial sodium channel (ENaC), respect-
ively; and autosomal dominant PHA1 due to mutations
of the NR3C2 gene encoding for the mineralocorticoid
receptor (MR) [5, 6]. Patients with autosomal recessive
PHA1 present not only severe lifelong renal salt-wasting,
but also salt-wasting from the lung, colon, sweat and
salivary glands. As a result, these patients experience re-
current salt-wasting crises, pulmonary infections, con-
gestion, coughing and wheezing, cholelithiasis, skin
infections, and miliaria rubra. Initial presentation is usu-
ally severe dehydration early after birth, but sometimes
autosomal recessive PHA1 has been diagnosed by neo-
natal cutaneous symptoms. These individuals are prone
to life-threatening salt-losing crises throughout their
lives. The pulmonary symptoms, clinically similar to
those of cystic fibrosis, are due to poor absorption of liq-
uids from airway surfaces and occur within weeks or
months from birth. To note, there have been no de-
scribed cases of neonatal respiratory distress in these pa-
tients. Instead, they experience recurrent lung infections
such as bronchopneumonia by different pathogens as
pseudomonas, pneumococcus, Staphylococcus aureus,
Klebsiella, and Serratia [7]. Autosomal dominant PHA1
clinical expression is milder and confined to the kidney.
Patients with autosomal dominant PHA1 generally
present with renal salt wasting that subsides after early
childhood. However, the presentation varies widely; it
can occur in infancy with salt wasting, growth retard-
ation, failure to thrive and occasionally death; or it can
present in adulthood. It may be unmasked by an illness
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that impairs oral intake of fluids and salt or results in
additional losses, such as viral gastroenteritis.
Secondary (transient) PHA is confined to the kidneys
and has been described in infants and children with
obstructive uropathy, pyelonephritis, tubulointerstitial
nephritis, sickle cell nephropathy, systemic lupus erythe-
matosus. Secondary PHA has been also related to drugs
like non-steroidal anti-inflammatory drugs and potas-
sium sparing diuretics [3, 6]. It represents the result of a
transient aldosterone resistance related to the kidney
infection, in children with or without a predisposing
renal malformation. The prognosis is good and the PHA
usually reverts with the resolution of the infection.
Primary selective hypoaldosteonism
Primary selective hypoaldosteonism is a rare autosomal
recessive disorder causing salt-wasting, accompanied by
vomiting, failure to thrive, and dehydration during the first
months of life. It is due to mutations in the CYP11B2 gene
encoding for a cytochrome P450 enzyme, termed aldoster-
one synthase (CYP11B2, P450c11AS). This enzyme
catalyzes the terminal steps in aldosterone biosynthesis
comprising the conversion of 11-deoxycorticosterone to
corticosterone, 18-hydroxycorticosterone, and finally aldo-
sterone. The aldosterone synthase is expressed exclusively
in the cells of the adrenal zona glomerulosa, limiting
the synthesis of aldosterone to that zone [8].
Familial glucocorticoid deficiency (FGD)
FGD, also known as hereditary unresponsiveness to
ACTH, is characterized by lack of response to ACTH
leading to adrenal insufficiency with subnormal gluco-
corticoid levels and remarkably elevated plasma ACTH
levels. Aldosterone secretion is generally preserved, but
hyponatremia at clinical presentation is common in in-
fants [9]. Mutations in the ACTH receptor gene (MC2R)
account for 25 % of FGD cases. Mutations in the mela-
nocortin receptor accessory protein gene (MRAP) ac-
count for 20 %, and mutations in the steroidogenic acute
regulatory protein (STAR) gene account for 2.5 % of
cases. Recently, mutations in the mini-chromosome
maintenance-deficient four homologue (MCM4) and
nicotinamide nucleotide transhydrogenase (NNT) genes,
involved in DNA replication and antioxidant defense,
and mutations in TXNRD2 gene, encoding the mito-
chondrial selenoprotein thioredoxin reductase 2, have
been also implicated [10–12].
X-linked adrenal hypoplasia congenita (AHC)
X-linked adrenal hypoplasia congenita (AHC) is a poten-
tially life-threatening condition characterized by primary
adrenal insufficiency associated with hypogonadotropic
hypogonadism Incidence was estimated to be about
1/12.500 births. This genetic disorder is caused by
mutations or deletions in NR0B1 gene located on the
short arm of chromosome X. NR0B1 gene encodes for a
nuclear receptor protein (DAX-1) which plays a key
role in regulating the development of adrenal cortex,
gonads, hypothalamus and pituitary gland. Salt-wasting
crisis is often the first clinical manifestation of AHC
occurring during the neonatal period, but timing and
clinical presentations of the disease may be variable
and characterized by non specific symptoms which can
occur during childhood or adolescence [13].
Autosomal adrenal hypoplasia congenita
The first description of steroidogenic factor 1 (SF-1)
protein abnormalities as a cause of human adrenal and
testicular dysgenesis was published more than 15 years
ago, and the spectrum of SF-1 associated conditions has
expanded rapidly. SF-1 is encoded by the NR5A1 gene.
Isolated PAI has been rarely associated with disruption
of SF-1, whereas a range of reproductive phenotypes are
more commonly seen, including 46 XY disorders of sex
development (DSD), with or without associated PAI,
male infertility and premature ovarian failure. Most
disease-associated variants are heterozygous, with rare
homozygous changes described [13].
Methods
The study was conducted at Bambino Gesù Children’s
Hospital (Rome, Italy). A retrospective chart review was
conducted for all patients with hyponatremia hospital-
ized during the first year of life, from 1st January 2006 to
31st December 2015. The selection criterion was repre-
sented by the referral to the Endocrinology Unit for
hyponatremia (serum sodium <130 mEq/L) of suspected
endocrine origin at admission. The diagnostic algorithm
routinely used in our hospital to address the differential
diagnosis of hyponatremia in infancy is summarized in
Fig. 1. The following data were collected from the
charts: clinical, biochemical and hormonal features at
initial presentation, additional clinical features, and
results of mutation analysis. The different candidate
genes were sequenced to identify mutations, based on
clinical characteristics and hormonal results of individual
patients.
Hormone assays
Plasma ACTH and serum cortisol were measured by
immunoluminometric assay and luminescence immu-
noassay (Nichols Institute, San Juan Capistrano, CA),
respectively. Mean inter- and intrassay variability coeffi-
cients of variation were <10 % and <4.8 %, respectively,
for both methods. Commercial kits were used to esti-
mate plasma renin (RIA, Sanofi-Pasteur), with mean
intra- and interassay coefficients of variation 7, 9 % and
10 %, respectively.
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Results
A total of 51 infants, admitted with significant hypona-
tremia (<130 mEq/l) and referred to the Endocrinology
Unit were identified (Fig. 2).
At the end of the diagnostic work-up, hyponatremia
was identified as related to chronic unrecognized salt
losses or reduced sodium intake in nine infants (17.6 %):
four infants with gastrointestinal diseases; three infants
with renal diseases; two cases of bottle-feeding exclu-
sively with over diluted rice milk not enriched with vita-
mins or minerals. In 10 infants (19.6 %) hyponatremia
was related to central nervous system diseases, suggest-
ing syndrome of inappropriate anti-diuretic hormone
secretion and/or cerebral salt wasting syndrome. All
these patients were excluded from the study.
In 19 patients (37.3 %) the final diagnosis was CAH. A
defect of 21-hydroxylase (CYP21A2 gene) was identified
in 18 CAH patients (five females). One newborn male
with perineal hypospadia and microphallus was found
affected by CAH related to 3β-Hydroxysteroid dehydro-
genase (3βHSD) deficiency due to mutations in HSD3B2
gene. Despite all the five newborn girls with 21-
hydroxylase CAH showed severe virilization of the exter-
nal genitalia (one girl with Prader stage 5; four girls with
Prader stage 4), they had been discharged from the
peripheral hospital where they were born with the alert
about the possibility of a salt-wasting crisis and an ap-
pointment for an endocrinologic evaluation in the out-
patient clinic, without undergoing any first-line
hormonal investigations before discharge.
Thirteen patients (25.5 %) were found affected by non-
CAH salt-wasting forms of adrenal origin (Table 1). Four
familial cases carrying the same NROB1 (DAX1) muta-
tion were identified in two families (four boys born from
two sisters). Two unrelated girls were found affected by
aldosterone synthase deficiency due to mutation of the
CYP11B2 gene. Two unrelated children (one male)
showed FGD due to MC2R mutations. One girl showed
autosomal recessive PHA1 related to compound hetero-
zygosity for two variants in intron eight of the SCNN1G
gene (c.1294 + 5G > A e c.1295-10 T > A). In this case
bioinformatics analysis showed that the first variation
abolished the 5' splice site and was probably pathogenic,
while the second variation was predicted to abolish the
3' splice site and to introduce a cryptic splice site of
unknown significance. Two cases of transient PHA were
identified, both of them were related to urinary infec-
tions in patients with renal malformations. Finally, in
two infants (one male) with a clinical and hormonal
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Fig. 1 Differential diagnosis and treatment of hyponatremia in infancy
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identified. Based on individual clinical details, CYP21A2,
CYP11B1, HSD3B2, CYP17A1, POR, NROB1 (DAX1)
and NR5A1 (SF1) genes were sequenced in both these
children. Very long chain fatty acids (VLCFA) were
measured in both patients, and were in the normal
range. In the boy, Smith-Lemli-Opitz syndrome was also
excluded by the study of DHCR7 gene, encoding for
7-dehydrocholesterol reductase.
Discussion
PAI is uncommon in the Western population; 90 to 140
subjects per 1 million people have been estimated to be
affected [14]. In contrast to the predominance of auto-
immune adrenal insufficiency in adults, most cases of
PAI in childhood show an inherited, monogenic origin
[15]. Genetic causes of paediatric PAI can be classified
into four major groups according to the underlying
51 infants admitted with hyponatremia 
and referred to the Endocrinology Unit
10 infants: urinary sodium >20
mEq/l  in subjects with central 
nervous system diseases 
32 infants: urinary sodium >20 mEq/l and clinical picture suggesting an  
adrenal defect  (concurrent dehydration, iperkalemia, hypoglycemia, 
metabolic acidosis, hyperpigmentation, DSD)
19 patients with congenital adrenal hyperplasia (CAH):
21-hydroxylase deficiency in 18 patients
-Hydroxysteroid dehydrogenase deficiency in 1 patient
13 patients with non-CAH salt-wasting forms of adrenal origin:
X-linked AHC in 4 cases, 
aldosterone synthase deficiency in 2 cases
FGD in 2 cases 
PHA1 in 1 case
transient PHA in 2 cases
unknown origin in 2 cases
2 perinatal hypoxic-ischemic encephalopathy
6 brain tumours
2 brain malformations
9 infants with varying urinary sodium and final diagnosis of:
gastrointestinal diseases (4 cases) 
renal diseases (3 cases)
bottle-feeding exclusively with plant milk (2 cases) 
Fig. 2 Flow diagram summarizing the recruitment procedure and the results. (CAH: congenital adrenal hyperplasia; AHC: X-linked adrenal hypoplasia
congenital, FGD: familial glucocorticoid deficiency, PHA: pseudohypoaldosteronism, DSD: disorders of sex development)
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pathogenesis: impaired steroidogenesis, adrenal hypopla-
sia, familial glucocorticoid deficiency (FGD), and adrenal
destruction. Congenital adrenal hyperplasia (CYP21A2,
CYP11B1, HSD3B2, CYP17A1, POR defects) constitutes
the largest subgroup of impaired steroidogenesis and
represents the most common cause of PAI in children
[15]. In contrast, different individually rare causes of
PAI as X-linked AHC (NR0B1/DAX-1), autosomal
adrenal hypoplasia (NR5A1/SF-1), congenital lipoid ad-
renal hyperplasia (CYP11A1, STAR gene defects), FGD,
adrenal autoimmune destruction and adrenoleukodys-
trophy (ABCD1) are now well established [15, 16].
Perry et al. [16] reported their 20-year experience with
PAI in 103 children <18 years old in Montreal, Canada.
An aetiology of PAI was identified in 94 % of cases: 72 %
were affected by CAH, 13 % had autoimmune adrenal
insufficiency, and the remaining 15 % had adrenoleuko-
dystrophy, rare syndromes (Wolman, Zellweger, etc.), or
unexplained adrenal insufficiency.
In a study performed in Melbourne, Australia [17] in
which only non-CAH cases were reported, there were
five cases each of autoimmune adrenal insufficiency,
adrenoleukodystrophy, and X-linked AHC and one case
of the IMAGE syndrome (characterized by intrauterine
growth retardation, metaphyseal dysplasia, adrenal hypo-
plasia congenita, and genital anomalies).
A recent study performed in a population from the
island portion of Newfoundland and Labrador, Canada,
reported mutation analysis of candidate genes in 11
patients with PAI. The aetiology of PAI was identified in
nine patients. One had a homozygous MC2R mutation
associated with FGD. Two had the same homozygous
mutation in the autoimmune regulator (AIRE) gene,
which is associated with type 1 autoimmune polyglandu-
lar syndrome. One patient had a heterozygous change in
AIRE gene of undetermined significance. Five were
homozygous for the same mutation of the gene encoding
the steroidogenic acute regulatory (STAR) protein
causing non-classic lipoid CAH. In the remaining two
patients, no clear aetiology was identified. In this study,
the high proportion of patients with non-classic lipoid
CAH strongly suggests a founder effect in a relatively
isolated population [18].
It is now emerging that a considerable overlap exists
in the clinical and biochemical presentation of the differ-
ent genetic forms of PAI. FGD can present with salt loss
suggestive of adrenal hypoplasia, and alterations in
STAR and CYP11A1 resulting in partial loss of protein
function may have a predominant FGD-like phenotype,
with glucocorticoid deficiency without genital abnormal-
ities in 46,XY newborns [18, 19].
To our knowledge, this is the first study focusing on
salt-wasting and hyponatremia as clinical presentation of
congenital adrenal defects in infancy. Our Institution is
the main Children’s Hospital of Lazio region, in the
central Italy. In Lazio region, the neonatal screening for
CAH is not performed. Our Institution does not include
a department of Obstetrics and sick newborn babies are
referred to us from peripheral birth hospitals. In female
babies, CAH is more easily suspected due to the pres-
ence of genital abnormalities. Female babies are usually
referred immediately after birth, before the onset of an
overt electrolyte imbalance. This probably explains why
in our population, selected on the basis of hyponatremia
at the first observation, the number of females with
CAH was significantly lower than the number of males.
Nevertheless, all the five girls with CAH showed hypona-
tremia at the first outpatient consultation, without overt
dehydration and salt wasting, and were admitted to con-
firm CAH diagnosis and start treatment. As expected, the
number of patients affected by the other forms of salt
wasting of adrenal origin was low, and a genetic cause was
not found in two patients. Surprisingly, in our study the
proportion of patients with primary selective hypoaldos-
teronism (two unrelated cases) was relatively high, consid-
ering that the estimated incidence of this defect is
probably <1/1,000,000/year [20, 21]. One case of aldoster-
one synthase (CYP11B2) deficiency and the case affected
by 3β-Hydroxysteroid dehydrogenase (3βHSD) deficiency
were previously described [22, 23].
Severe salt-wasting with hyponatremia is caused by min-
eralocorticoid deficiency or complete adrenal insufficiency
(both glucocorticoid and mineralocorticoid deficiency),
but also infants with isolated severe glucocorticoid defi-
ciency and preserved aldosterone secretion may present
with mild hyponatremia, which is usually transient. Inter-
estingly, both patients with severe FGD due to MC2R
mutations showed mild hyponatremia at onset, without
dehydration and overt salt-wasting. It has been described
that in severe glucocorticoid deficiency plasma anti-
diuretic hormone (ADH) levels are elevated, because of
the decreased effective circulating blood volume, impair-
ing the ability to dilute the urine. Cortisol acts as a
negative feedback mechanism on both CRH and ADH
secretion. ADH is cosecreted with CRF by the paraven-
tricular nuclei. If cortisol levels are chronically low, the
amount of ADH can continue to increase causing dilu-
tional hyponatremia [2].
Conclusions
Emergency management of newborns infants presenting
with dehydration and salt wasting requires correction of
water losses and treatment of electrolyte imbalances.
Nevertheless, the differential diagnosis between congeni-
tal PAI and PHA may be difficult in emergency settings,
and sometimes hospitalized infants presenting with salt-
wasting and metabolic acidosis are immediately started
on mineralocorticoid and glucocorticoid therapy to avoid
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life-threatening complications, before the correct diag-
nosis is reached [4, 24, 25]. Steroid therapy (with both
glucocorticoids and mineralocorticoids) is life-saving in
PAI, while it is not effective in restoring salt and water
balance in PHA. After correction of dehydration, chil-
dren with aldosterone synthase deficiency require
mineralocorticoid therapy only, even if stress doses of
glucocorticoids administered intravenously are able to
restore the electrolyte balance because cortisol is able
to bind the MR [20, 21]. Physicians involved in the
management of infants with salt wasting of suspected
endocrine origin should remember that, whenever prac-
ticable, a blood sample for the essential hormonal in-
vestigations (ACTH, cortisol, 17 OH progesterone,
androstenedione, renin, aldosterone) should be col-
lected before starting steroid therapy, to guide the sub-
sequent diagnostic procedures and in particular to
address the analysis of candidate genes.
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